CH₃CH₃
AI image · google/nano-banana-2-lite
official

Prime Peptides: an FDA warning letter over retatrutide, and the retatrutide still in stock two years later

by ch3ch3 · 3d ago · 0 comments

Vendor active also Prime Vitality, Inc., Prime Vitality Inc, primepeptides.co, Prime primepeptides.co
C
#18 of 54 vendors audit better than 68% of them · what people say 50/100
Our grade serious findings
58/ 100

scored on 10 of 12 criteria · 2 could not be told

Readers’ grade no ratings yet
  • Accuracy –
  • Delivery –
  • Service –
  • Honesty –
  • Overall –

Be the first. The form below takes about twenty seconds and needs no account.

The score above weighs both: ours is what the record shows, theirs is what people who dealt with this entity say.

  • Is there an identifiable legal operator: a registered name, a jurisdiction, an address that resolves?

    a California corporation, Prime Vitality, Inc., named by FDA and by the store itself, at two Santa Barbara suite addresses; no state registry record cited

    Evidence: [4][5][6]

  • How long has it operated, by evidence: first archive capture, domain registration, oldest attributable post?

    domain registered January 2024, selling retatrutide by May 2024, still selling in October 2026

    Evidence: [1][2]

  • Does it publish third-party certificates of analysis for what it sells?

    lot-numbered certificates from seven laboratories; one checked against its laboratory's portal and matched; the most frequent lab's verification keys are unchecked; two labs have domains younger than the store; one certificate identifies semaglutide by a code

    Evidence: [19][27][28][29][31][30][32]

  • Where there are results, do they agree with the label, the marketing and the reported effects?

    three certificates read; each finds the labelled amount or more (10.63 of 10 mg, 30.59 of 30 mg, 11.43 of 10 mg); the semaglutide vial is 14% over, a dosing error for anyone who measures by the label

    Evidence: [27][29][31]

  • Are contents and amounts stated on the product?

    the vials in the certificate photos name the compound and the amount; the shop's page called retatrutide GLP-3 for some weeks in 2025

    Evidence: [27][29]

  • No disease claims, no 'safe', no borrowed botanical names for synthetic compounds?

    the disease claims FDA quoted; after the letter a Weight Loss Peptides collection, reviews describing appetite on the retatrutide page, a sign-up for prescribers; a made-in-the-USA claim a year after calling such claims undocumented

    Evidence: [4][10][11][22][5][25]

  • Pattern of complaints about orders not arriving, long delays, no tracking?

    no buyer report found on Reddit; the store's own reviews are not counted

    Evidence: [33]

  • Pattern of complaints about wrong, inert, contaminated or mislabelled product?

    no buyer report found on Reddit

    Evidence: [33]

  • Chargebacks refused, refunds unanswered, processors dropped?

    a 30-day return window and refunds to the original payment method, stated since 2025; no complaint found

    Evidence: [6][34]

  • Warning letters, seizures, lawsuits, attorney-general actions, platform bans?

    FDA warning letter, December 2024, for retatrutide and semaglutide as unapproved new drugs; both still sold, retatrutide in stock in October 2026; no response or close-out on FDA's index

    Evidence: [4][8][11][18]

  • Is there any attempt to keep minors out?

    a click-through box: 21 and over in 2025 and early 2026, 18 and over by October 2026

    Evidence: [24][22][19]

  • Does it say what the legal status of what it sells is, honestly, where it ships?

    research use only on two drugs FDA told it in writing were unapproved new drugs, which it kept selling; a registration for medical providers; no statement of legal status beyond the disclaimer

    Evidence: [4][21][23][22]

Operating since
at least 2024-01-31 (the domain was registered 2024-01-31; first archived storefront 2024-02-29; selling retatrutide by May 2024)
Where
Prime Vitality, Inc. dba Prime Peptides, 735 State St., Ste 422, Santa Barbara, California (the address on FDA's warning letter, December 2024); 133 E De La Guerra St Ste 14, Santa Barbara, California (the contact and return-policy pages, archived October 2026)
Presence
primepeptidesco primepeptidesco @PrimePeptide
Verified
every quotation checked against its document on 2026-11-18; 34 sources

What they sell, and what we think is in it

  • Retatrutide (sold as Reta and GLP-3 in spring 2025) Peptides GLP-3 works by activating three different hormone receptors: GLP-1, GIP, and glucagon Retatrutide
  • Semaglutide (sold as GLP-1 in May 2025) Peptides Intended Use: Semaglutide is designed for Research Purposes only. Semaglutide
  • Tirzepatide (members only, July 2025) Peptides Tirzepatide Tirzepatide
  • GLP-2 Peptides Identity: GLP TZ a GLP product the certificates identify only by the code GLP TZ
  • BPC-157 and blends (GLOW, KLOW, Wolverine) Peptides BPC-157 (Blue Cap) BPC-157 with TB-500, GHK-Cu and KPV in the blends
  • Melanotan I and II Peptides Melanotan II Green Cap Melanotan II and melanotan I
  • Selank and Semax Nootropics Selank / Semax (20mg) SelankSemax
  • Tesamorelin, sermorelin, ipamorelin, MOTS-c, NAD+, glutathione and others Peptides Tesamorelin 10mg (Purple Cap) tesamorelin, sermorelin, ipamorelin, CJC-1295, AOD-9604, MOTS-c, NAD+ and glutathione
  • Bacteriostatic water Other BAC Water Blue Cap a solvent for dissolving the powders

Molecules named in this dossier

Pulse what people say about Prime Peptides

✓ 0 good 0 bad ✕

One tap, no account. Then for up to 36 Methyls.

The long read

Who they say they are, and what the record says

Prime Peptides sells research peptides from primepeptides.co. The domain was registered on 31 January 2024, and its owner's name is withheld from the public record.⁠[1] By May 2024 the shop was selling retatrutide, Eli Lilly's investigational weight-loss drug, which no regulator has approved.⁠[2] In May 2024 its About page said the shop was born from the passion of its founder, "a marketer and biohacker whose quest for personal enhancement fuels our company" mission, and that the founder's hands-on experience with every peptide "anchors our product authenticity".⁠[3]

The company behind it is named twice. FDA addressed its warning letter to "Prime Vitality, Inc. dba Prime Peptides" at "735 State St., Ste 422" in Santa Barbara, California.⁠[4] The store's own Sourcing page opens "At Prime Vitality Inc (Prime Peptides)".⁠[5] By 2026 the contact and return pages give a different Santa Barbara address, "133 E De La Guerra St Ste 14".⁠[6]

The warning letter

On 10 December 2024 FDA's Center for Drug Evaluation and Research sent the company a warning letter by email. FDA had reviewed the shop's website in October 2024, along with its Facebook, Instagram and YouTube accounts, and concluded that "your “Semaglutide” and “Retatrutide” products are unapproved new drugs".⁠[4]

The letter addresses the shop's disclaimer head on: "Despite statements on your product labeling marketing your products for “research purposes only” and “not for human consumption or clinical use,” evidence obtained from your website establishes that your products are intended to be drugs for human use."⁠[4] The evidence it quotes:

  • Product pages. "Retatrutide improves glycemic control." "Retatrutide reduces liver fat." "Semaglutide reduces cardiovascular events." Each was followed by figures from human trials.⁠[4] The September 2024 retatrutide page still carries them, under a heading "Study on Weight Loss", a line below "Intended Use: Retatrutide is designed for Research Purposes only."⁠[7]
  • A blog post, "Top Peptides for Weight Loss: A Quick Guide", illustrated with a woman measuring her waist.⁠[4]
  • Social media. Customer testimonials posted by the shop, among them one headed "Impressive Weight Loss": "Retatrutide has been impressive for my weight loss journey."⁠[4]
  • YouTube. A video titled "Top 5 Peptides for Weight Loss".⁠[4]

FDA asked for a written answer "within fifteen working days of receipt of this letter" and warned: "Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction."⁠[4] On 18 November 2026 FDA's index listed no response and no close-out letter for this company.⁠[8]

Selling before the letter is not a finding of this dossier. What the shop did after it is.

After the letter: same product, new words, briefly a new name

The text changed, the product stayed. Eight days after the letter, the semaglutide page was archived with the product in stock, under the line "Intended Use: Semaglutide is designed for Research Purposes only."⁠[9] On 14 January 2025 the home page still listed retatrutide and semaglutide, next to a collection called "Weight Loss Peptides".⁠[10] On 21 January the retatrutide page, at the address FDA had quoted, sold a 10 mg vial for $160, in stock according to the page's own data. The disease claims were gone. In their place: "Retatrutide is a versatile tool for research into receptor signaling and metabolic pathways." and "Retatrutide is provided exclusively for research purposes".⁠[11]

A product page headed Retatrutide, with a 4.80 star rating, a price of $160.00, a Guaranteed Fast Delivery badge, a single 10mg size option and an Add to Cart button. Below, a section headed What is Retatrutide? describes a synthetic peptide acting on three receptors, ideal for controlled lab research, not human use. The product photo has not loaded.
Figure 1. The retatrutide page on 21 January 2025, six weeks after FDA's letter: same address, same name, $160, and an add-to-cart button. The disease claims the letter quoted are gone; the product is not. (Rendered without the site's scripts, so the photo is missing.)⁠[11]

The reviews the shop displayed on that page told a different story. One read "Am finding I feel fullness earlier today than" before. Another began "I am currently in my second and a half weeks of the Retatrutide research" and went on: "While my appetite has remained similar to what I experienced with Semaglutide".⁠[11] The capture does not date the reviews. The shop was displaying them six weeks after the letter.

Reta, then GLP-3. By late April the retatrutide page had moved to a new address under the name "Reta", in 10 and 30 mg, in stock. Its text said "Intended Use: Retatrutide is designed for Research Purposes only."⁠[12] On 14 May the same product was called GLP-3. The price and sizes were the same, $170 and $315, and so were the stock codes in the page data, RT10 and RT30. It was in stock, and the description said: "GLP-3 works by activating three different hormone receptors: GLP-1, GIP, and glucagon."⁠[13] Retatrutide is the drug that acts on those three receptors. The page then explained what that does in the body: "Together, they tell the body to release insulin, slow down food movement in the stomach, and improve how the body handles fats and sugars."⁠[13] The semaglutide page was renamed the same way, to GLP-1 (stock codes SM5, SM10 and SM15): "Intended Use: GLP-1 is designed for Research Purposes only."⁠[14] The certificates page that month listed "GLP-1", "GLP-2", "GLP-3" and "GLP-4".⁠[15]

A product page headed GLP-3, priced $170.00, with size options 10mg and 30mg and an Add to Cart button. A grey box says all products are for laboratory research purposes only, not for human consumption, and that the buyer must be 21 or older. Below, text describes an investigational triple receptor agonist targeting GLP-1, GIP and glucagon receptors.
Figure 2. 14 May 2025: the same product as GLP-3, at the price and in the sizes of the April 'Reta' page, with the same stock codes in the page data. It was in stock. A month later the name was retatrutide again.⁠[13]

Retatrutide again. The code names did not last. In June 2025 the store moved to new software, and the product was called Retatrutide again, though its text still said "Intended Use: GLP-3 is designed for Research Purposes only."⁠[16] The page showed 249 vials of one size and 282 of the other in stock. By November 2025 the text said retatrutide throughout, a 60 mg vial had been added, and a button offered "View Test Results".⁠[17] On 2 October 2026 the page sold retatrutide by name, from $110, all three sizes in stock.⁠[18] The tracker of Lilly's retatrutide suits lists the shop among fourteen that received FDA letters, with this page.

In all, the drug FDA named was off the shop's product names for some weeks in the spring of 2025. Every capture of the product page that we read shows it in stock.

Semaglutide stayed on sale too. The October 2026 Testing page lists certificates for semaglutide lots dated up to September 2026.⁠[19] In July 2025 a "Members Only" product tag listed "Tirzepatide", the active ingredient of Lilly's Mounjaro and Zepbound.⁠[20]

Who it sells to

The shop says its products are not for people. Every page carries a research-use disclaimer, and the home page's FAQ answers "What dose should I take?" with "Please conduct independent research or speak to a licensed medical professional."⁠[21]

It also invites prescribers. A "Medical Provider Registration" page asks for a "National Provider Identifier (NPI)", the number US health-care providers bill under, and says "We will review and approve/deny your application within 48 hours."⁠[22] The link is in the footer of the 2026 home page.⁠[21] The page does not say what a medical provider account gets.

The shipping page says the shop cannot "ship to Ohio at this time".⁠[23] It does not say why.

Where it is made, in four versions

The site has described its supply chain four ways in two years.

  1. June 2025. The About page became a "Manufacturing Process of Prime Peptides Research-Grade Peptides". It says the process "is conducted in our manufacturing facility". One of the listed steps is "Electrospray Ionization (ESI) and Sodium Introduction".⁠[24] Electrospray ionization is the name of a way of feeding a sample into a mass spectrometer, an analytical instrument. The page does not explain what it means as a manufacturing step.
  2. November 2025. The Sourcing page says "Nearly every competitor relies on overseas production for their APIs." Competitors who claim "made in the USA", it says, "generally lack documentation to substantiate that claim". Prime's own "raw APIs come from trusted, advanced facilities in Asia", and "Our Santa Barbara headquarters oversees finishing, final formulation, and packaging". It adds: "Our sterility testing is done in-house for every batch."⁠[5]
  3. October 2026. The shipping page says "Every order is packed by our own team in Santa Barbara, California and ships with tracking."⁠[23]
  4. November 2026. The About page is headed "Research peptides, made in the USA and proven." It says "Every Prime vial goes through the same controlled process at our partner facility in North Carolina," and "Purity and identity are verified by Freedom Diagnostics, an independent US lab, not by us."⁠[25] The page names neither the North Carolina facility nor the source of the raw material. It also says: "Very few can show you the factory, the lab, or the lot number behind the vial in your hand."⁠[25]

A year after writing that competitors' "made in the USA" claims "generally lack documentation to substantiate that claim", the shop made the claim itself, and named no factory.⁠[5][25]

Lab results

The shop publishes a lot-numbered certificate for most products. In June 2025 its Testing page said that "All of our peptides undergo rigorous third-party purity testing conducted by Janoshik Analytics".⁠[26] By October 2026 the page lists certificates from seven laboratories: Janoshik, "Lab: Bioviridian", "Lab: Kovera Labs", "Lab: Freedom Diagnostic", "Lab: Horizon Analytical", "Lab: Accumark Labs" and "Lab: Vanguard Laboratory".⁠[19] We read three of the retatrutide and semaglutide certificates.

  • Retatrutide, 10 mg, lot 3202026RT. Bioviridian's certificate COA3941, issued 24 April 2026, identifies retatrutide by mass spectrometry and reports 10.63 mg at 99.8% purity, with endotoxin below its limit.⁠[27] We looked up the number on the laboratory's portal on 18 November 2026. It serves the same file, byte for byte.⁠[28]

A one-page certificate of analysis headed Bioviridian, COA3941, sample received April 22, 2026, issued April 24, 2026, for vendor Prime Peptides, sample Retatrutide 10mg, lot 3202026RT. Results: identity retatrutide by MALDI-MS, content 10.63 mg, purity 99.8%, endotoxin below 0.05 EU/mL, all marked Conforms. A chromatogram, a mass spectrum and a photo of a black-capped vial labelled Prime Peptides Retatrutide 10mg.
Figure 3. Bioviridian's April 2026 certificate for a 10 mg retatrutide lot: 10.63 mg found, at 99.8%. The laboratory's portal serves the same file, byte for byte.⁠[27]

  • Retatrutide, 30 mg, batch 7162026RT. Kovera Labs' report KVR-2026-214CAB, certified 20 August 2026, reports 30.59 mg at 99.786%, identity by LC-MS, endotoxin pass and no microbial growth.⁠[29] Two details in the report do not fit together. Its endotoxin page describes a kinetic chromogenic assay in the text and a kinetic turbidimetric one in the results table. And the sample was received and certified on the same day, 20 August, while the sterility page states a two-day incubation.⁠[29] The report does not explain either. Kovera's domain was registered on 2 January 2026.⁠[30]

A certificate of analysis from Kovera Labs, report KVR-2026-214CAB, client Prime Peptides, certified 08/20/2026. Sample: retatrutide, batch 7162026RT, lyophilized powder, labelled 30 mg, orange cap. Results: purity 99.786%, net content 30.59 mg, identity retatrutide by LC-MS, endotoxin pass, microbial sterility no growth. A chromatogram and a photo of an orange-capped vial labelled Retatrutide 30mg.
Figure 4. Kovera Labs' August 2026 certificate for a 30 mg retatrutide lot: 30.59 mg found. The report was certified on the day the sample was received, though its sterility page describes a two-day incubation.⁠[29]

  • Semaglutide, 10 mg, lot 26072401. Freedom Diagnostics' certificate, reported 5 August 2026, finds 11.43 mg at 99.91%, which is 14% more than the label. The identity line gives a code, GLP SM, not the name of a compound.⁠[31] The store's Testing page gives the identity of its GLP-2 lots the same way: "Identity: GLP TZ".⁠[19] Freedom Diagnostics' domain was registered on 14 February 2025.⁠[32]

A certificate of analysis from Freedom Diagnostics for client Prime Peptides, lot 26072401, received 07/31/2026, reported 8/5/2026. Product: Sema, 10mg. Purity 99.91%, net content 11.43 mg, identity confirmed, endotoxin pass, microbial analysis pass. In the analytical results the identity is given as GLP SM. A photo shows two red-capped vials, one labelled Sema 10mg.
Figure 5. Freedom Diagnostics' August 2026 certificate for a 10 mg semaglutide lot: 11.43 mg found, 14% over the label. The identity line reads GLP SM, not semaglutide.⁠[31]

All three find the labelled amount or more. Most of the certificates on the Testing page come from Janoshik and carry a verification key. None of those keys is checked in this dossier.

Bioviridian also signs certificates for American Peptides and Cenexa Labs, two shops Eli Lilly sued in October 2026. A shared testing laboratory is common among peptide sellers, and on its own it connects nothing else. We have no independent test of a Prime Peptides product.

What buyers report

On 18 November 2026 we searched the Arctic Shift archive of r/Peptides (18,427 posts since 1 September 2025) and r/Retatrutide (20,000 posts since 7 June 2026) for the name. Six posts name a "Prime Peptides". Four are about an Australian shop of the same name, one is a discount code for a different store, and one was removed with no text and no replies.⁠[33] None is a report about this store. The shop's own reviews are not counted here. Delivery and quality are therefore unknown, not clean.

Regulatory and legal

FDA warning letter, December 2024. Covered above. FDA named retatrutide and semaglutide as unapproved new drugs and quoted the shop's disease claims.⁠[4] Both drugs were still on sale in 2026.⁠[18][19] As of 18 November 2026 FDA's index shows no response from the company and no close-out letter.⁠[8] We found no lawsuit, seizure or state action against the company.

Research use only. The disclaimer FDA quoted is still on every page. The FAQ points readers who ask about doses to "a licensed medical professional", and the provider registration asks for an NPI.⁠[21][22]

Age. In 2025 a click-through box said "You must be at least 21 to visit this site."⁠[24] The provider page in February 2026 said "You must be 21+ to purchase Peptides products".⁠[22] By October 2026 the box said "You must be 18 years of age or older to use this website."⁠[19]

Payment. The 2025 policy said "We have a 30-day return policy", with refunds to the original payment method.⁠[34] The 2026 page keeps it: "We offer a 30-day return window."⁠[6] We found no complaint about refunds.

Still open

  • The company. FDA and the store name Prime Vitality, Inc. of Santa Barbara. We have no state record of it, and the two addresses on file are suites at different street addresses.
  • Where it is made. "facilities in Asia" in November 2025, "made in the USA" at a partner facility in North Carolina a year later. Neither is named, and we found no registration or inspection record behind either.
  • The certificates. The Janoshik keys are unchecked, and the Kovera report has two internal inconsistencies the laboratory has not been asked about.
  • The letter. FDA's index shows no response. Whether the company answered privately, and what it said, is not public.

Changes

2026-11-18: first published.

References

  1. Registry WHOIS for primepeptides.co (CentralNic, created 2024-01-31, registrar GoDaddy, registrant withheld), read 2026-11-18 — ICANN lookup
  2. primepeptides.co, Retatrutide product page, archived 2024-05-19 — Wayback Machine
  3. primepeptides.co, About Us, archived 2024-05-14 — Wayback Machine
  4. Warning letter to Prime Vitality, Inc. dba Prime Peptides (MARCS-CMS 695156), 2024-12-10 — US Food and Drug Administration
  5. primepeptides.co, Sourcing, archived 2025-11-12 — Wayback Machine
  6. primepeptides.co, Return Policy, archived 2026-10-05 — Wayback Machine
  7. primepeptides.co, Retatrutide product page, archived 2024-09-20 — Wayback Machine
  8. FDA warning-letter index searched for 'prime peptides' and 'prime vitality', 2026-11-18 (one letter to this company; the second 'prime vitality' result is an unrelated company; no response or close-out letter listed) — U.S. Food and Drug Administration
  9. primepeptides.co, Semaglutide product page, archived 2024-12-18 — Wayback Machine
  10. primepeptides.co home page, archived 2025-01-14 — Wayback Machine
  11. primepeptides.co, Retatrutide product page, archived 2025-01-21 — Wayback Machine
  12. primepeptides.co, Reta product page, archived 2025-04-29 — Wayback Machine
  13. primepeptides.co, GLP-3 product page, archived 2025-05-14 — Wayback Machine
  14. primepeptides.co, GLP-1 product page, archived 2025-05-14 — Wayback Machine
  15. primepeptides.co, Certificates of Analysis, archived 2025-05-14 — Wayback Machine
  16. primepeptides.co, Retatrutide product page, archived 2025-06-20 — Wayback Machine
  17. primepeptides.co, Retatrutide product page, archived 2025-11-12 — Wayback Machine
  18. primepeptides.co, Retatrutide product page, archived 2026-10-02 — Wayback Machine
  19. primepeptides.co, Testing, archived 2026-10-05 — Wayback Machine
  20. primepeptides.co, product tag Members Only, archived 2025-07-15 — Wayback Machine
  21. primepeptides.co home page, archived 2026-10-02 — Wayback Machine
  22. primepeptides.co, Medical Provider Account Registration, archived 2026-02-14 — Wayback Machine
  23. primepeptides.co, Shipping Policy, archived 2026-10-07 — Wayback Machine
  24. primepeptides.co, About Us, archived 2025-06-20 — Wayback Machine
  25. primepeptides.co, About Us, archived 2026-11-12 — Wayback Machine
  26. primepeptides.co, Testing, archived 2025-06-20 — Wayback Machine
  27. Certificate of analysis COA3941, Retatrutide 10mg, lot 3202026RT, Bioviridian Inc., issued 2026-04-24, as published by the store (archived 2026-10-09; image-only PDF) — Wayback Machine
  28. Certificate of analysis COA3941, as the laboratory's portal serves it on 2026-11-18 (byte-identical to the copy the store published) — Bioviridian Inc.
  29. Kovera Labs report KVR-2026-214CAB, Retatrutide 30 mg, batch 7162026RT, certified 2026-08-20, with endotoxin and sterility pages, as published by the store (archived 2026-10-20) — Wayback Machine
  30. RDAP record for koveralabs.com (registered 2026-01-02), read 2026-11-18 — Verisign RDAP
  31. Freedom Diagnostics certificate, Sema 10mg, lot 26072401, reported 2026-08-05, as published by the store (archived 2026-10-20) — Wayback Machine
  32. RDAP record for freedomdiagnosticstesting.com (registered 2025-02-14), read 2026-11-18 — Verisign RDAP
  33. r/Peptides posts 2025-09-01 to 2026-11-18 (18,427) and r/Retatrutide posts 2026-06-07 to 2026-11-18 (20,000), through the Arctic Shift archive, searched for 'prime peptides' on 2026-11-18: six posts, none about this store — Arctic Shift — anecdotal report, not evidence
  34. primepeptides.co, Refund policy, archived 2025-02-20 — Wayback Machine
0

What readers say

Anyone can rate here, with or without an account. One rating per person; a second submission edits the first.

Readers’ grade no ratings yet
  • Accuracy –
  • Delivery –
  • Service –
  • Honesty –
  • Overall –

Be the first. The form below takes about twenty seconds and needs no account.

Rate Prime Peptides

One to five on each. Your experience, not a verdict on the record; our own grade is separate.

AccuracyIt was what it said it was
DeliveryIt arrived, when it should have
ServiceQuestions and problems were answered
HonestyLabels and results told the truth
OverallOverall trust
0/600
Posting as guest

Comments

Sign in to join the conversation.

No comments yet.

Tell us something